GMP-like mRNA Manufacturing Services

GMP-like mRNA Manufacturing Services

Accelerate your mRNA project to IND

Home » IVT RNA Production Services » IVT mRNA Production » GMP-like mRNA Manufacturing Services

Overview

GenScript offers high-quality, scalable, and regulatory-compliant mRNA production to support your preclinical, IND, and early-phase clinical studies.

We provide comprehensive support across all key preclinical stages—including assay design for preclinical optimization, assay qualification for clinical trial readiness, analytical procedures and method development, stability studies under various environmental stressors, and toxicology studies for preclinical safety assessment.

All processes are conducted in Grade C clean room environments to ensure consistent quality and minimize contamination risks.

Our GMP-like services bridge the gap between research and full cGMP manufacturing, accelerating time to market while ensuring cost efficiency.

Rush mRNA Synthesis New!

GMP-like mRNA Manufacturing Services

Catalog IVT mRNA, circRNA, saRNA, LNP products

mRNA QC Analysis

GenScript Cap Technology

Circular RNA Synthesis

Self-Amplifying RNA

LNP Formulation

Targeted LNP Formulation

ReadyEdit LNP Formulation

Accelerated Timelines for Preclinical and IND-Enabling Studies

Our GMP-like service is designed to fast-track your mRNA development process. With optimized workflows and rapid turnaround times, we help you move from research to IND submission more quickly—without compromising on quality.

Scalable and Customizable Production

Whether you're developing a vaccine, therapeutic, or genetic medicine, we offer flexible options in mRNA design—cap structures, modifications, poly(A) tail length, and comprehensive QC testing—to support your specific scientific and regulatory needs at scale.

Phase-Appropriate Quality with Regulatory Alignment

We offer rigorous quality control and documentation, including batch records, CoAs, and TSE/BSE statements, performed under Grade C clean room conditions. The quality of mRNA drug substances and products depends on their design, manufacturing process, and the specifications applied throughout development. Our testing approach includes validated analytical methods for starting materials, in-process monitoring, release, and stability to ensure product consistency, safety, and efficacy. We assess critical quality attributes—such as identity, purity, integrity, potency, and encapsulation efficiency—at each stage to support comparability, shelf-life, and IND-enabling decisions.

Service Highlights

Licensable GenScript Cap™ Technology

Leverages a proprietary co-transcriptional capping method to deliver mRNA with ≥95% capping efficiency, enhancing transcript stability and translation yield

Strong Expertise in optimized IVT system to improve yield & reduce dsRNA

6,200+ projects delivered. Expertise in mRNA codon optimization, UTR engineering, and ORF screening based on your target application

IVT mRNA Synthesis & Characterization

Strong mRNA characterization platform and experienced team to provide advanced QC analysis for RNA characterization and support your IND filing data preparation

Comparison with Research and GMP-like

GMP-like mRNA

RUO mRNA

Intended Use

Preclinical & IND-enabling studies

Research only (e.g., screening, discovery)

Cleanroom Standard

Grade C cleanroom environment; ISO classified production suites

Not required

Quality Control (QC)

Preclinical QC including identity, purity, quantity, physical state (integrity) and safety aligned with USP guidelines

Standard QC (e.g., RNA length, purity, impurity)

Regulatory Compliance

IND support documentation, CoA, TSE/BSE statements

No regulatory documentation

Documentation Provided

Batch records, CoA, preclinical-grade documentation, TSE/BSE, manufacturing summary report

Basic data sheet

Process Traceability

Full traceability with controlled procedures

Limited

Customizability

Fully customizable with phase-appropriate QC, documentation, process development/engineering

Sequence, modifications, tail length

Typical Use Cases

Toxicology, biodistribution, IND submissions

Screening, basic functional studies

Turnaround Time

From 7 weeks, flexible based on customers’ requirement

Fast 2 weeks

Additional Capabilities

Master cell bank generation, product-specific master batch records, environmental monitoring

-

Why Choose GenScript’s GMP-like mRNA Manufacturing?

mRNA Development Pathway: From RUO to pre-clinical stage from 7 weeks

Comprehensive mRNA Cap, Tail, and QC Configuration for Preclinical Use

Selecting the Cap

No Cap

Cap 0

Cap1AG: m7G(5’)pppA(2’-O-Me)pG

Cap1AU: m7G(5’)pppA(2’-O-Me)pU

GenScript Cap™ (Patented technology)

Other. Customer provided Cap analogues

UTR and Sequence

Proprietary UTRs designed for tissue-specific and tumor-targeted expression

Enable customized mRNA design for greater expression control and application-specific performance

GenSmart or X5 codon optimization for higher expression

Modifications and PolyA tail length

Modifications

N1-Me-Ψ

5moU

Ψ & 5meC

Cy5-UTP or Thio-CTP

Unmodified

PolyA tail length

100A tail

Custom tail ≤ 120A

No tail

QC methods

Preclinical standard

Preclinical upgrade

Our GMP-like mRNA services follow the latest industry guidance and cover extensive quality control attributes including identity, integrity, purity, potency, and safety.

QC Specifications

Identity

Sequencing

Sanger Sequencing

> 98% alignment

NGS by Illumina

Q20 Ratio > 95%

Content

Concentration

UV Absorbance

0.5 - 2.0 mg/mL or Target ± 5%

Qubit

Length

mRNA Length

TapeStation

Target ± 15%

Capillary Electrophoresis

Agarose Gel Electrophoresis

Expected band size detected

Purity

A260/280 Ratio

UV Specification

1.70 - 2.30

Size-Based Purity

< 5kb: ≥85% > 5kb: ​≥80%

Capping Efficiency

Enzyme Digestion to LC-MS

≥ 95%

Poly(A) Tail Length

Target ± 5%

Residual Protein

NanoOrange Assay

≤ 0.1%

Residual DNA Template

qPCR

≤ 0.05%

dsRNA

Immunoblot

ELISA

Aggregate mRNA

SEC-HPLC

< 20%

Fragment mRNA

RP-HPLC

< 25%

Safety

Endotoxin

Quantitative

< 1 EU/mg

Bioburden

Direct Inoculation

No growth after 72 hours

Other

Appearance

Visual Inspection

Clear and free of foreign particles

pH

pH Strip or pH meter

Target ± 0.5

Buffer Specification

Client Specification

N/A

Partner with GenScript

With over 20 years of nucleic acid expertise and a global track record in biologics manufacturing, GenScript is your trusted partner for early-stage mRNA development. Whether you are optimizing a new therapeutic or preparing for clinical scale-up, our GMP-like service is designed to help you move fast, stay compliant, and reduce risk .

Start Your Project

Contact us to discuss your project and receive a free consultation on how GenScript’s GMP-like mRNA services can support your pipeline.

FAQ

GMP-like follows near-GMP standards but is optimized for speed and cost in early development, whereas full GMP is required for Phase I/II/III and commercial supply. Schedule a consult

We offer a comprehensive QC panel covering identity, integrity, purity, potency, residual DNA/RNA template, endotoxin, sterility, and encapsulation efficiency (for LNPs RUO). Stability testing and method development support are also available to ensure product shelf-life and regulatory readiness.

We can provide cGMP mRNA through our sister company ProBio. Please contact our technical support team.

Related Services

Discover and Screening services

First in the market to achieve Gene-to-mRNA in just 3 weeks to drive innovations with our cutting-edge mRNA, circular RNA, and self-amplifying RNA technologies.

LNP Formulation

GenScript proudly offers lipid nanoparticle (LNP) formulation services for mRNA and circular RNA drug research and development service.

Get in Touch with GenScript IVT mRNA Production Services

REQUEST A QUOTE

EMAIL

[email protected]

PHONE

1-877-436-7274

ONLINE FORM

Online Quote Submission

FAX

1-732-210-0262

Our QC tests cover identity, content integrity, purity, potency, and safety attributes

RNA length by CE + size-based integrity by CE

Percentage of RNA Fragments: IPRP-HPLC

Poly A Tail Length: Enzyme digestion+ LCMS

Capping efficiency: Enzyme digestion +LCMS

Total Protein Residue: Nano Orange Assay

Plasmid DNA Residue: qPCR Assay

dsRNA residue: Immunoblot Assay or ELISA Assay

RNA Aggregation Assay: SEC-HPLC

Endotoxin by chromogenic LAL

Bioburden